
Customer Validation
- •Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1309-17.
Description |
NPS-2143 is a novel potent and selective antagonist of Ca2+ receptor with IC50 of 43 nM. |
---|---|
IC50 & Target |
IC50: 43 nM (Ca2+ receptor) |
In Vitro |
NPS-2143 blocks increases in cytoplasmic Ca2+ concentrations with IC50 of 43 nM elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor. NPS-2143 stimulates parathyroid hormone (PTH) secretion from bovine parathyroid cells with EC50 of 41 nM. Moreover, NPS 214 also blocks the inhibitory effects of calcimimetic NPS R-467 on PTH secretion from bovine parathyroid cells and the inhibitory effects of extracellular Ca2+ on isoproterenol-stimulated increases in cyclic AMP formation[1]. In HEK-293 cells transiently expressing hCaSRs, NPS-2143 significantly suppresses the kokumi taste by effectively inhibiting the activity of both GSH and γ-Glu-Val-Gly[3]. A recent study shows that NPS-2143 treatment suppresses low molecular weight fractions of azuki hydrolysate-induced cholecystokinin (CCK) secretion in CaSR-transfected HEK 293 cells[4]. |
In Vivo |
NPS-2143 results in a rapid 4- to 5-fold increase in plasma PTH levels and also a transient increase in plasma Ca2+ levels[1] in rats. In normotensive rats, NPS-2143 administration (1 mg/kg, i.v.) markedly increases mean arterial blood pressure (MAP) in the presence of parathyroid glands[2]. |
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kinase Assay
[1] |
This clonal cell line, referred to as HEK 293 4.0-7 cells, are used in a high-throughput screening format to detect agonists and allosteric activators of the Ca2+ receptor. Changes in the concentration of cytoplasmic [Ca2+]i provide a quantitative and functional assessment of Ca2+ receptor activity in these cells and the results using this assay parallel those obtained using a homologous expression system of bovine parathyroid cells. On-line continuous measurements of fluorescence in fluo-3- or fura-2-loaded HEK 293 4.0-7 cells are obtained using a custom-built spectrofluorimeter or a fluorescence imaging plate reader instrument. NPS-2143 is incubated with cells for 1 minute before increasing the concentration of extracellular Ca2+ from 1.0 mM to 1.75 mM. NPS-2143 is tested individually at a concentration of 100 μg/mL (20 μM-80 μM) and those causing more than a 40% inhibition of the control response are considered to be biologically active. To determine the potencies (IC50) of NPS-2143 with biological activity, concentration-response curves are obtained and then, as an initial assessment of selectivity, the effects of NPS-2143 on [Ca2+]i evoked by other G protein-coupled receptors are examined at a concentration several times their IC50. Wild-type HEK 293 cells (and HEK 293 4.0-7 cells) express receptors for thrombin, bradykinin, and ATP, which couple to the mobilization of intracellular Ca2+. These responses can be studied to quickly assess any nonselective action of compounds on G protein-coupled receptors. Additional assays for selectivity include HEK 293 cells engineered to express receptors most homologous in sequence and topology to the Ca2+ receptor. These include native or chimeric receptors for various metabotropic glutamate and γ-aminobutyric acid type B receptors (GABABRs). Chimeric receptors are created using partial sequences of metabotropic glutamate receptors and Ca2+ receptors, engineered to couple to activation of phospholipase C and release of intracellular Ca2+ in HEK 293 cells. NPS-2143 lacking pan-activity are then subjected to structural modifications and their potencies and selectivities monitored using these HEK 293 4.0-7 cell assays in an iterative process. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[1] |
NPS-2143 is formulated in 20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin. On the day of study, the rats are infused intravenously (0.1 mL/kg·min) for 120 min with NPS-2143 (0.1 μmol/kg·min) or vehicle, a 20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin. Blood samples (0.5 mL) are collected before and at various times after the start of the infusion for measurements of plasma levels of PTH and Ca2+. To prevent excessive blood volume loss during the course of the experiment, for each blood sample the erythrocyte pellet is resuspended in an equal volume of normal rat plasma and reinjected. Plasma levels of Ca2+ are measured immediately after collection using a model 634 ionized calcium analyzer. PTH levels are measured using the Immutopics rat PTH(1-34) immunoradiometric assay kit. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
References |
|
Molecular Weight |
408.92 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₂₄H₂₅ClN₂O₂ |
||||||||||||
CAS No. |
284035-33-2 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
10 mM in DMSO NPS-2143 is dissolved into DMSO as 10 mM of stock solution, and aliquots are diluted into 100 mL perfusion buffer just before use[5]. * "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
||||||||||||
References |
|
Purity: 99.42%
COA (92 KB) HNMR (492 KB) LCMS (114 KB)
Handling Instructions (1252 KB)-
[1]. Nemeth EF, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323-31.
[2]. Rybczynska A, et al. Hypertensive effect of calcilytic NPS 2143 administration in rats. J Endocrinol. 2006 Oct;191(1):189-95.
[3]. Ohsu T, et al. Involvement of the calcium-sensing receptor in human taste perception. J Biol Chem. 2010 Jan 8;285(2):1016-22.
[4]. Nakajima S, et al. Calcium-sensing receptor mediates dietary peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res. 2012 May;56(5):753-60.
[5]. Sun J, et al. Calcium-sensing receptor: a sensor and mediator of ischemic preconditioning in the heart. Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1309-17.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
如题,之前没做过药代,老师给了一个600+Da的五肽,想测下药代动参数,看文献推荐上述两种方法,但是不知道选哪种更好,lcms前处理会不会影响小肽。
就是蛋白质分子的小片断
是氨基酸形成的
有机的是有机化合物的简称,它指的是含碳化合物.
但是,有四大类常见物质一般不作为有机物处理:
1、碳的氧化物,如CO和CO2.
2、碳酸及其盐,如CaCO3.
3、金属碳化物,如CaC2.
4、拟卤素及其化合物,如(CN)2与KSCN.
水的化学式为H2O,它不含有碳元素,故不是有机物.
但若所描述的水不是化学意义的水,而是自然界存在的天然水,那么,水中会溶有一定量的有机物.
求助大家,小分子药物最新专利申请情况跟踪,之前听别人说可以在一个网站可以导出这个信息。
不知哪位大侠知道,告知一下,不胜感激!
一、首先你要明白肽是什么...........................肽是氨基酸通过酰胺键结合而成的东西.........
二、你要明白氨基酸是什么..........................氨基酸是构成蛋白质的基本单位,多种氨基酸结合为长肽链,几条长肽链再盘旋就形成了蛋白质......................
三、关于小分子肽、短肽、多肽、寡肽.......其实都是肽.......区别只是由多少个氨基酸构成而已............
所以,你的问题可以很粗暴地理解为“蛋白质对人体有没有副作用”.......
如果你营养足够的情况下,再补充这个,会导致营养过剩,从而加重身体代谢的负荷............类似就是这样子的了...........小分子肽,一般现在用于化妆品上比较多(一ye子.植物肽面膜就是这个).......小分子肽(可以简单理解为纳米胶原蛋白),这比蛋白质(也可以粗暴理解为胶原蛋白)更加容易吸收......而用在食品上,要视乎是何种小分子肽了.....大豆肽、花生肽、大米肽....不同的肽有不同的功效.......主要可以改善风味、改善吸收、增强胃肠道功能等等.......
2017年4月26日|Filedunder:制药工业,制药企业,孤儿药,新药研发,制药常识,文献综合|Postedby:路人丙
【新闻事件】:在日前正在举行的美国神经学年会上MitsubishiTanabe公布了其ALS药物Edaravone的一个三期临床试验结果。在标准疗法基础上加入Edaravone显著改善ALS患者综合功能指标ALSFRS-R(-5.0对-7.5),同时也改善运动、呼吸等局部功能。Edaravone已经在韩国日本批准用于ALS,去年10月申请在美国上市,今年6月之前有望批准。
【药源解析】:ALS全称叫“肌肉萎缩性侧面硬化病”,也称LouGehrig氏病,因为30年代美国纽约洋基棒球队著名选手LouGehrig死于这个病。2014年风行一时的冰桶挑战让更多人知道了ALS,但ALS新药发现依然缓慢。美国目前只有riluzole这一个上市药物,能增加~10%的一年生存机会。
ALS的发病机理未知,动物模型十分不可靠,所以这个病的新药开发很难。过去10年大约只有十几个药物进入临床,基本全军覆没。走的最远的是百建艾迪的dexpramipexole,2013年初在三期临床失败。Edaravone号称是游离基清除剂,但分子机理未知。Edaravone最早作为中风药物开发,后来扩展到ALS。第一个三期临床失败,今天公布的是症状较轻患者。这个临床是日本人群,Edaravone并没有在美国IND和开展临床试验,所以如果批准将是比较特殊的情况(和Marathon的DMD药物Emflaza情况类似)。
Edaravone的另一个特殊性质是其分子结构。这个化合物分子十分简单,分子量只有174,可以算作是超小分子药物。现在有几十个分子量小于200的FDA批准药物,这类药物因为官能团数目有限不大可能与任何靶点有较高结合能,所以通常靶点未知。靶点未知又没有可靠动物模型,这类药物发现就更加困难。当然动物模型预测性差不是超小分子药物才面临的难题,多数神经系统药物、甚至现在最火热的肿瘤免疫疗法也面临同样问题。
这种临床前缺乏可靠评价体系的药物可以算是有D无R,这要求厂家冒更大的临床风险。只有潜在回报较大如没有任何标准疗法的罕见病或真正颠覆性药物如免疫疗法才可以适当采用这个模式。这个模式扩大化对厂家的长期生存是个威胁,因为新药的未知因素已经很多、成功率已经很低。没有临床前适当去风险的机会主义不可持续。
转发分享
美中药源原创文章,转载注明出处并添加超链接,商业用途需经书面授权。
★更多深度解析访问《美中药源》~
https://www.yypharm.com/?p=10664

